Data Sheet 2_Cardioprotective effect of Yiqi Huoxue decoction on post-myocardial infarction injury mediated by Ca2+ flux through MAMs.pdf by Yufei Li (433737)

“…It ameliorated MAMs ultrastructure and function, enhancing CypD, MCU, Sig-1R, and NOGO-B expression while reducing IP3R2, GRP75, and VDAC1. in vitro, YQHX significantly increased viability, reduced oxygen-glucose deprivation-induced mPTP opening and Ca²⁺ levels, upregulated CypD, MCU, Sig-1R, and NOGO-B, and downregulated IP3R2, GRP75, and VDAC1. …”

Data Sheet 1_Cardioprotective effect of Yiqi Huoxue decoction on post-myocardial infarction injury mediated by Ca2+ flux through MAMs.pdf by Yufei Li (433737)

“…It ameliorated MAMs ultrastructure and function, enhancing CypD, MCU, Sig-1R, and NOGO-B expression while reducing IP3R2, GRP75, and VDAC1. in vitro, YQHX significantly increased viability, reduced oxygen-glucose deprivation-induced mPTP opening and Ca²⁺ levels, upregulated CypD, MCU, Sig-1R, and NOGO-B, and downregulated IP3R2, GRP75, and VDAC1. …”

Image 4_Cardioprotective effect of Yiqi Huoxue decoction on post-myocardial infarction injury mediated by Ca2+ flux through MAMs.pdf by Yufei Li (433737)

“…It ameliorated MAMs ultrastructure and function, enhancing CypD, MCU, Sig-1R, and NOGO-B expression while reducing IP3R2, GRP75, and VDAC1. in vitro, YQHX significantly increased viability, reduced oxygen-glucose deprivation-induced mPTP opening and Ca²⁺ levels, upregulated CypD, MCU, Sig-1R, and NOGO-B, and downregulated IP3R2, GRP75, and VDAC1. …”

Image 2_Cardioprotective effect of Yiqi Huoxue decoction on post-myocardial infarction injury mediated by Ca2+ flux through MAMs.pdf by Yufei Li (433737)

“…It ameliorated MAMs ultrastructure and function, enhancing CypD, MCU, Sig-1R, and NOGO-B expression while reducing IP3R2, GRP75, and VDAC1. in vitro, YQHX significantly increased viability, reduced oxygen-glucose deprivation-induced mPTP opening and Ca²⁺ levels, upregulated CypD, MCU, Sig-1R, and NOGO-B, and downregulated IP3R2, GRP75, and VDAC1. …”

Image 1_Cardioprotective effect of Yiqi Huoxue decoction on post-myocardial infarction injury mediated by Ca2+ flux through MAMs.pdf by Yufei Li (433737)

“…It ameliorated MAMs ultrastructure and function, enhancing CypD, MCU, Sig-1R, and NOGO-B expression while reducing IP3R2, GRP75, and VDAC1. in vitro, YQHX significantly increased viability, reduced oxygen-glucose deprivation-induced mPTP opening and Ca²⁺ levels, upregulated CypD, MCU, Sig-1R, and NOGO-B, and downregulated IP3R2, GRP75, and VDAC1. …”

Image 3_Cardioprotective effect of Yiqi Huoxue decoction on post-myocardial infarction injury mediated by Ca2+ flux through MAMs.pdf by Yufei Li (433737)

“…It ameliorated MAMs ultrastructure and function, enhancing CypD, MCU, Sig-1R, and NOGO-B expression while reducing IP3R2, GRP75, and VDAC1. in vitro, YQHX significantly increased viability, reduced oxygen-glucose deprivation-induced mPTP opening and Ca²⁺ levels, upregulated CypD, MCU, Sig-1R, and NOGO-B, and downregulated IP3R2, GRP75, and VDAC1. …”

Data Sheet 4_Cardioprotective effect of Yiqi Huoxue decoction on post-myocardial infarction injury mediated by Ca2+ flux through MAMs.pdf by Yufei Li (433737)

“…It ameliorated MAMs ultrastructure and function, enhancing CypD, MCU, Sig-1R, and NOGO-B expression while reducing IP3R2, GRP75, and VDAC1. in vitro, YQHX significantly increased viability, reduced oxygen-glucose deprivation-induced mPTP opening and Ca²⁺ levels, upregulated CypD, MCU, Sig-1R, and NOGO-B, and downregulated IP3R2, GRP75, and VDAC1. …”

Data Sheet 3_Cardioprotective effect of Yiqi Huoxue decoction on post-myocardial infarction injury mediated by Ca2+ flux through MAMs.pdf by Yufei Li (433737)

“…It ameliorated MAMs ultrastructure and function, enhancing CypD, MCU, Sig-1R, and NOGO-B expression while reducing IP3R2, GRP75, and VDAC1. in vitro, YQHX significantly increased viability, reduced oxygen-glucose deprivation-induced mPTP opening and Ca²⁺ levels, upregulated CypD, MCU, Sig-1R, and NOGO-B, and downregulated IP3R2, GRP75, and VDAC1. …”

Data Sheet 14_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”

Data Sheet 1_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”

Data_Sheet_1_MakC and MakD are two proteins associated with a tripartite toxin of Vibrio cholerae.pdf by Nandita Bodra (19793703)

“…Through deletion mutant analysis, we found that individual deletions of makC or makD do not significantly affect MakA expression or secretion. However, the deletion of both makC and makD impairs the expression of MakB, which is directly downstream, and decreases the expression of MakE, which is separated from makCD by two genes. …”

Data Sheet 8_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”

Data Sheet 15_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”

Data Sheet 13_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”

Data Sheet 2_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”

Data Sheet 10_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”

Table 1_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.xlsx by Didar Murad (12220805)

“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”

Data Sheet 6_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.xlsx by Didar Murad (12220805)

“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”

Data Sheet 5_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.xlsx by Didar Murad (12220805)

“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”

Data Sheet 10_Unravelling the impact of SARS-CoV-2 on hemostatic and complement systems: a systems immunology perspective.pdf by Didar Murad (12220805)

“…Simulation results highlight key components affected, including thrombin, tissue plasminogen activator, plasmin, fibrin degradation products, interleukin 6 (IL-6), the IL-6 and IL-6R complex, and the terminal complement complex (C5b-9). We explored that the decreased levels of complement factor H and C1-inhibitor significantly elevate these components, whereas tissue factor pathway inhibitor and alpha-2-macroglobulin have more modest effects. …”